KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non-Current Assets for 9 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 4.6% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, down 4.6% year-over-year, with the annual reading at $7.2 million for FY2025, 4.6% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $7.2 million at Xenon Pharmaceuticals, up from $7.1 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $9.2 million in Q2 2025, with the low at $7.1 million in Q3 2025.
  • Average Other Non-Current Assets over 4 years is $7.7 million, with a median of $7.5 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets decreased 8.2% in 2024, then rose 23.89% in 2025.
  • Over 4 years, Other Non-Current Assets stood at $7.8 million in 2022, then dropped by 4.58% to $7.4 million in 2023, then grew by 1.35% to $7.5 million in 2024, then decreased by 4.6% to $7.2 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $7.2 million, $7.1 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.